vTv Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
vTv Therapeutics Inc. (VTVT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 3.68% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2026-03-10
- vTv Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2025 was 3.68%, a 6.98% increase from fiscal 2024.
- vTv Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2024 was 3.44%, a 0.58% increase from fiscal 2023.
- vTv Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2023 was 3.42%, a 115.09% increase from fiscal 2022.
- vTv Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2022 was 1.59%, a 59.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month |
|---|---|
| 2025-12-31 | 3.68% 10-K · filed 2026-03-10 |
| 2024-12-31 | 3.44% 10-K · filed 2026-03-10 |
| 2023-12-31 | 3.42% 10-K · filed 2026-03-10 |
| 2022-12-31 | 1.59% 10-K · filed 2025-03-20 |
| 2021-12-31 | 1.00% 10-K · filed 2024-03-13 |